Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Assistive Technology : the Official Journal of RESNA|February 6, 2004
Reliability of bench tests of interface pressureStephen Sprigle, William Dunlop, Larry PressAdvances in Therapy|April 17, 2016
FP/FORM Versus FP/SAL Within Clinical Practice: An Updated Budget Impact Analysis in AsthmaEmily Farrington, Alison Saunders, Louise Heron, et al.Advances in Therapy|November 7, 2013
Budget impact analysis of a fixed-dose combination of fluticasone propionate and formoterol fumarate (FP/FORM) in a pressurized metered-dose inhaler (pMDI) for asthmaWilliam Dunlop, Louise Heron, Georgia Fox, et al.Clinicoeconomics and Outcomes Research : CEOR|November 9, 2013
Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference valuesWilliam Dunlop, Itrat Iqbal, Ifty Khan, et al.Journal of Medical Economics|February 9, 2012
Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysisWilliam Dunlop, Reiner Uhl, Iftekhar Khan, et al.BMC Medical Education|September 1, 2023
'A human face and voice': transgender patient-educator and medical student perspectives on gender-diversity teachingKy Ruprecht, William Dunlop, Estee Wah, et al.Journal of Personality|November 2, 2024
Using Intersectionality to Understand How Structural Domains Are Embedded in Life NarrativesDulce Wilkinson Westberg, Moin Syed, Aerika Brittian Loyd, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 8, 2012
Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysisBeth Woods, Neil Hawkins, William Dunlop, et al.Journal of Medical Economics|December 7, 2013
Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and WalesSarah Dewilde, Beth Woods, Jean-Gabriel Castaigne, et al.Pageof 2